Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.34 |
| ▸ | LPL | P06858 | 5/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL425267 | 0.82 | LPL (0.38) | EGFRFFAR1AAK1LPLLIPG | |
| SCHEMBL9986782 | 0.80 | FFAR1 (0.37) | FFAR1AAK1LPLLIPGDGAT1 | |
| SCHEMBL3239432 | 0.77 | LPL (0.38) | AAK1LPLLIPGCA1CA2 | |
| SCHEMBL14956934 | 0.75 | LPL (0.37) | EGFRFFAR1AAK1LPLLIPG | |
| SCHEMBL26334789 | 0.75 | FFAR1 (0.34) | FFAR1AAK1LPLLIPGDGAT1 | |
| SCHEMBL18736534 | 0.75 | FFAR1 (0.37) | FFAR1AAK1LPLLIPGDGAT1 | |
| SCHEMBL22182200 | 0.74 | CA1 (0.35) | FFAR1AAK1LPLLIPGDGAT1 | |
| SCHEMBL6314664 | 0.73 | POLB (0.33) | CA1CA9 | |
| SCHEMBL14956695 | 0.73 | LPL (0.41) | EGFRAAK1LPLLIPGCA1 | |
| SCHEMBL14962342 | 0.73 | LPL (0.40) | AAK1LPLLIPGCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267706-A1 | Compounds, Compositions and Methods Comprising Pyridazine Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-10-21 | — | — | US | disclosed |
| US-20100267706-A1 | Compounds, Compositions and Methods Comprising Pyridazine Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-10-21 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090270398-A1 | Compounds, Compositions and Methods Comprising Pyridazine Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-29 | — | — | US | disclosed |
| WO-2009131947-A2 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270398-A1 | Compounds, Compositions and Methods Comprising Pyridazine Derivatives | CFTR, PKD1, PKD2 | EGFR 355/4885FFAR1 946/4885AAK1 2312/4885 |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | CFTR, PKD1, PKD2 | EGFR 260/4885FFAR1 1350/4885AAK1 3604/4885 |
| US-20100267706-A1 | Compounds, Compositions and Methods Comprising Pyridazine Derivatives | CFTR, PKD1, PKD2 | EGFR 391/4885FFAR1 1473/4885AAK1 2588/4885 |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | CFTR, PKD1, PKD2 | EGFR 260/4885FFAR1 1350/4885AAK1 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.